Participant flow

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma · Source last updated 2017-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles

   id

   FG000

   title

   Carfilzomib (A0)

2. description

   In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16. If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles.

   id

   FG001

   title

   Carfilzomib (A1)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         13

      2. group Id

         FG001

         num Subjects

         33

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         22

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         23

      2. group Id

         FG001

         num Subjects

         157

      type

      Progressive Disease

   4. reasons

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         14

      type

      various reasons

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         46

      2. group Id

         FG001

         num Subjects

         266

      type

      STARTED

   2. achievements

      1. comment

         Number of patients who completed 12 cycles of treatment

         group Id

         FG000

         num Subjects

         4

      2. comment

         Number of patients who completed 12 cycles of treatment

         group Id

         FG001

         num Subjects

         40

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         42

      2. group Id

         FG001

         num Subjects

         226

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Results of this study are reported in 2 parts, depending on whether a patient was enrolled and treated under the original protocol (referred to as 'A0') or under Amendment 1 and subsequent amendments (referred to as 'A1').

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice